Eric Adler was named President and Chief Executive Officer of Lexeo Therapeutics, Inc. As of November 14, 2026, Lexeo Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 27, 2026 to April 30, 2026, naming 3 appointments (Form 8-K, January 27, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Lexeo Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lexeo Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-27 to 2026-04-30. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Lexeo Therapeutics, Inc. files it.
Also on the record for Lexeo Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 9.8% of the class | 5%+ stakes | Source |
| November 10, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.4% of the class | 5%+ stakes | Source |
| October 13, 2026 | Stake report, Schedule 13G, by JPMORGAN CHASE & CO. | 5.5% of the class | 5%+ stakes | Source |
| September 29, 2026 | Acquired Mantle Therapeutics Inc. | — | Acquisition | Source |
| August 14, 2026 | Stake report, Schedule 13G, by OrbiMed Advisors LLC | 4.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Paradigm BioCapital Advisors LP | 5.3% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 8.4% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Balyasny Asset Management L.P. | 9.69% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Paradigm BioCapital Advisors LP | 8.3% of the class | 5%+ stakes | Source |
| April 13, 2026 | Stake report, Schedule 13G, by SUVRETTA CAPITAL MANAGEMENT, LLC | 7.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lexeo Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Lexeo Therapeutics, Inc. and the records around it.
Lexeo Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Acquisition Sep 2026
- Who owns it
Companies that share a holder
- Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: ZENAS BIOPHARMA, INC. (Oct 2025), CG Oncology, Inc. (Sep 2025)
- Affinity Asset Advisors, LLC also filed stake reports on 16 other companies: Amanat Acquisition Corp. (Nov 2026), Equillium Inc. (Nov 2026), Forte Biosciences, Inc. (Nov 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
Watch Lexeo Therapeutics, Inc.
Get an email when Lexeo Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lexeo Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lexeo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexeo Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 35 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-30 | Reported | not named in the filing | 8-K, 2026-04-30 | ||
| 2026-01-27 | In | Chief Operating Officer | 2026-01-02 | 8-K, 2026-01-27 | |
| 2026-01-27 | In | Chief Medical Officer | 2026-01-20 | 8-K, 2026-01-27 | |
| 2026-01-27 | In | President and Chief Executive Officer | 8-K, 2026-01-27 |
Who leads Lexeo Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President and Chief Executive Officer: Eric Adler, appointed (filed 2026-01-27).
- Chief Medical Officer: Narinder P. Bhalla, appointed, effective 2026-01-20 (filed 2026-01-27).
- Chief Operating Officer: Jose Manuel Otero, appointed, effective 2026-01-02 (filed 2026-01-27).
New leaders reset buying decisions — get the Full Report on Lexeo Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Lexeo Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Operating Officer at Lexeo Therapeutics, Inc.Every change, in the filing's words
Reported
(d) Appointment of New Director On April 28, 2026 (the " Appointment Date "), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the " Board ") of Lexeo Therapeutics, Inc. (the " Company ").
- Dr. Sepp-Lorenzino will serve as a director with a term of office expiring at the Company's 2028 Annual Meeting of Stockholders.
- As of the Appointment Date, the Board also appointed Dr. Sepp-Lorenzino as a member of the Company's Science and Technology Committee.
- Dr. Sepp-Lorenzino, age 65, has served as Principal of GNMmeds LLC, a consulting firm focused on genomic medicine research and development, since January 2025.
- Dr. Sepp-Lorenzino has also served as a member of the boards of directors of Taysha Gene Therapies, Inc., a publicly traded biotechnology company, since November 2020, AskBio Inc., a wholly owned, independently operated subsidiary of Bayer AG, since April 2025, and URSA Medicines, a private biotech company, since September 2025.
- Dr. Sepp-Lorenzino previously served as Executive Vice President, Chief Scientific Officer of Intellia Therapeutics, Inc., a publicly traded biotechnology company, from May 2019 to January 2025 and as Scientific Advisor until December 2025.
- From 2017 to May 2019, Dr. Sepp-Lorenzino served as Vice President, Head of Nucleic Acid Therapies at Vertex Pharmaceuticals, Inc., a publicly traded biopharmaceutical company.
Appointed: Jose Manuel Otero, Chief Operating Officer, effective 2026-01-02
On January 27, 2026, Lexeo Therapeutics, Inc. (the "Company") announced that the Board of Directors of the Company (the "Board") appointed Jose Manuel Otero, Ph.D., the Company's current Chief Technical Officer, to serve as Chief Operating Officer of the Company, effective as of January 2, 2026.
Appointed: Narinder P. Bhalla, Chief Medical Officer, effective 2026-01-20
Chief Medical Officer Transition On January 27, 2026, the Company announced that the Board appointed Narinder P. Bhalla, M.D., to serve as the Company's Chief Medical Officer, effective as of January 20, 2026.
Appointed: Eric Adler, President and Chief Executive Officer
Dr. Adler will serve as President and Chief Executive Officer of Myoventive, Inc., a cardiac precision medicines company that was co-founded in June 2025 by the Company, Perceptive Xontogeny Venture Funds and venBio Partners.
- In connection with Dr. Otero's appointment, the compensation committee of the Board approved a new annual base salary for Dr. Otero of $510,000 per annum.
- Dr. Otero is otherwise continuing under the terms of his existing compensation arrangement with the Company.
- Dr. Bhalla succeeds Eric Adler, M.D., the Company's Head of Research.
- Effective on January 27, 2026, Dr. Adler will no longer be an executive officer of the Company within the meaning of the rules promulgated under the Exchange Act.
- He will remain a senior clinical and scientific advisor to the Company.
Tools for this story
Each opens in a new tab, filled in for Lexeo Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
